Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple Sclerosis

Summary

This study will assess the efficacy and safety of MBP8298 compared to placebo in subjects with Secondary Progressive Multiple Sclerosis (SPMS)

Timeline

Start

2007-06

Primary completion

2009-07

Completion

2009-09

Outcome

Missed primary endpoint

Stopped: “Negative efficacy results of the MAESTRO-01 study”

release “dirucotide did not meet the primary endpoint of delaying disease progression, as measured by the Expanded Disability Status Scale (EDSS), during the two-year MAESTRO-01” lilly.com ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	dirucotide	Protein / enzyme biologic	500 mg	Intravenous

Indications